Filed
by the Registrant ý
|
||
Filed
by a Party other than the Registrant o
|
||
Check
the appropriate box:
|
||
o
|
Preliminary
Proxy Statement
|
|
o
|
Confidential,
for Use of the Commission Only (as permitted by Rule
14a-6(e)(2))
|
|
ý
|
Definitive
Proxy Statement
|
|
o
|
Definitive
Additional Materials
|
|
o
|
Soliciting
Material Pursuant to Rule 14a-11(c) or Rule
14a-12
|
CYTORI
THERAPEUTICS, INC.
|
|||||
(Name
of Registrant as Specified In Its Charter)
|
|||||
|
|||||
(Name
of Person(s) Filing Proxy Statement, if other than the
Registrant)
|
|||||
Payment
of Filing Fee (Check the appropriate box):
|
|||||
ý
|
No
fee required
|
||||
o
|
Fee
computed on table below per Exchange Act Rules 14a-6(i)(4) and
0-11
|
||||
(1)
|
Title
of each class of securities to which transaction applies:
|
||||
(2)
|
Aggregate
number of securities to which transaction applies:
|
||||
(3)
|
Per
unit price or other underlying value of transaction computed pursuant to
Exchange Act Rule 0-11:
|
||||
(4)
|
Proposed
maximum aggregate value of transaction:
|
||||
(5)
|
Total
fee paid:
|
||||
o
|
Fee
paid previously with preliminary materials.
|
||||
o
|
Check
box if any part of the fee is offset as provided by Exchange Act Rule
0-11(a)(2) and identify the filing for which the offsetting fee was paid
previously. Identify the previous filing by registration statement number,
or the Form or Schedule and the date of its filing.
|
||||
(1)
|
Amount
Previously Paid:
|
||||
(2)
|
Form,
Schedule or Registration Statement No.:
|
||||
(3)
|
Filing
Party:
|
||||
(4)
|
Date
Filed:
|
|
•
|
Elect
directors;
|
|
•
|
Ratify
the Audit Committee’s selection of KPMG LLP as our independent registered
public accounting firm for the 2009 fiscal year; and
|
|
•
|
Transact
any other business that is proposed in accordance with our by-laws before
the Annual Meeting is finally
adjourned.
|
·
|
“FOR” the election of
each listed nominee for director;
and
|
·
|
“FOR” ratification of
KPMG LLP as our independent registered public accounting firm for the 2009
fiscal year.
|
·
|
We
may contact you using the telephone or electronic
communication;
|
·
|
Our
directors, officers, or other regular employees may contact you
personally; or
|
·
|
We
may hire agents for the sole purpose of contacting you regarding your
proxy.
|
Name
|
Age
|
Position
|
Ronald
D. Henriksen
|
70
|
Chairman
of the Board of Directors
|
Christopher
J. Calhoun
|
43
|
Chief
Executive Officer and Director
|
Marc
H. Hedrick, MD
|
46
|
President
and Director
|
Richard
J. Hawkins
|
60
|
Director
|
Paul
W. Hawran
|
57
|
Director
|
E.
Carmack Holmes, MD
|
71
|
Director
|
David
M. Rickey
|
53
|
Director
|
·
|
Makes
recommendations to the Committee regarding the base salary, bonus and
stock option award levels for our other executive officers;
and
|
·
|
Provides
an annual recommendation to the Committee regarding overall Company
performance objectives for the year and the individual performance
objectives of each of our executive officers with respect to our Executive
Management Incentive Compensation Plan, and reports to the Committee on
the satisfaction of each such
objective.
|
Name
and Address of Beneficial Owner (1)
|
Number
of Shares of Common Stock Owned (2)
|
Number
of Shares of Common Stock Subject to Options Exercisable Within 60 Days
(3)
|
Total
Number of Shares of Common Stock Beneficially Owned (4)
|
Percent
Ownership
|
||||
Olympus
Corporation
|
4,013,043
|
594,406
|
4,607,449
|
13.3%
|
||||
Shinjuku Monolith, 3-1
Nishi-Shinjuku 2-Chome
Shinjuku-ku,Tokyo
163-0914, Japan
|
||||||||
Neil
Gagnon (5)
|
2,806,724
|
266,925
|
3,073,649
|
8.9%
|
||||
1370 Avenue of the
Americas,Suite 2400
New York, NY
10019
|
||||||||
Green
Hospital Supply, Inc.
|
3,000,000
|
—
|
3,000,000
|
8.8%
|
||||
3-20-8 Kasuga
Suita-City
Osaka 565-0853,
Japan
|
||||||||
Christopher
J. Calhoun
|
120,000
|
1,001,872
|
1,121,872
|
3.2%
|
||||
Marc
H. Hedrick, MD
|
440,038
|
407,707
|
847,745
|
2.5%
|
||||
Mark
E. Saad
|
76,500
|
370,623
|
447,123
|
1.3%
|
||||
Bruce
A. Reuter
|
4,193
|
300,102
|
304,295
|
*
|
||||
Seijiro
N. Shirahama
|
8,700
|
257,915
|
266,615
|
*
|
||||
David
M. Rickey
|
168,558
|
99,374
|
267,932
|
*
|
||||
Ronald
D. Henriksen
|
23,161
|
238,542
|
261,703
|
*
|
||||
E.
Carmack Holmes, MD
|
15,161
|
184,374
|
199,535
|
*
|
||||
Paul
W. Hawran
|
—
|
114,374
|
114,374
|
*
|
||||
Richard
J. Hawkins
|
—
|
38,750
|
38,750
|
*
|
||||
All
executive officers and directors as a group (13)
|
865,511
|
3,285,737
|
4,151,248
|
11.1%
|
*
|
Represents
beneficial ownership of less than one percent (1%) of the outstanding
shares as of April 15, 2009.
|
(1)
|
Unless
otherwise indicated, the address of each of the named individuals is c/o
Cytori Therapeutics, Inc., 3020 Callan Road, San Diego, CA
92121.
|
(2)
|
Represents
shares of outstanding common stock owned by the named parties as of April
15, 2009.
|
(3)
|
Shares
of common stock subject to stock options currently exercisable or
exercisable within 60 days of April 15, 2009 are deemed to be outstanding
for computing the percentage ownership of the person holding such options
and the percentage ownership of any group of which the holder is a member,
but are not deemed outstanding for computing the percentage of any other
person.
|
(4)
|
The
amounts and percentages of common stock beneficially owned are reported on
the basis of regulations of the Securities and Exchange Commission
governing the determination of beneficial ownership of securities. Under
the rules of the Commission, a person is deemed to be a “beneficial owner”
of a security if that person has or shares “voting power,” which includes
the power to vote or to direct the voting of such security, or “investment
power,” which includes the power to dispose of or to direct the
disposition of such security. A person is also deemed to be a beneficial
owner of any securities for which that person has a right to acquire
beneficial ownership within 60
days.
|
(5)
|
Information
reported is based on a Schedule 13G as filed with the Securities and
Exchange Commission on February 18, 2009. According to the Schedule 13G,
Mr. Gagnon has (i) sole power to vote or to direct the vote of 1,542,925
shares; (ii) shared power to vote or to direct the vote of 1,431,091
shares; (iii) sole power to dispose or to direct the disposition of
1,542,925 shares; and (iv) shared power to dispose or to direct
the disposition of 1,530,724 shares. Mr. Gagnon is the managing
member and the principal owner of Gagnon Securities LLC. In its role as
investment manager to certain funds (the “Funds”), Gagnon Securities LLC
shares investment and/or voting power with Mr. Gagnon over certain
securities of the Company that are owned by the Funds and may be deemed to
be the beneficial owner of these
securities.
|
Name
|
Age
|
Position(s)
|
Christopher
J. Calhoun
|
43
|
Chief
Executive Officer
|
Marc
H. Hedrick, MD
|
46
|
President
|
Mark
E. Saad
|
39
|
Chief
Financial Officer
|
Seijiro
N. Shirahama
|
55
|
President
— Asia Pacific
|
Bruce
A. Reuter
|
60
|
Senior
Vice President — International Sales, Marketing &
Distribution
|
Douglas
Arm, Ph.D.
|
40
|
Sr.
Vice President — Operations
|
Alexander
M. Milstein, MD
|
50
|
Vice
President — Clinical Development
|
Kenneth
K. Kleinhenz.
|
45
|
Vice
President — Quality & Regulatory
Affairs
|
·
|
Evaluated
our total executive compensation structure (base pay, bonus and equity) by
reference to proxy statements and other public company information for the
peer groups described below;
|
·
|
Generated
a report identifying market compensation practices our comparability to
those practices for each executive position;
and
|
·
|
Made
recommendations to the Committee regarding compensation strategies for the
Company.
|
·
|
Focus
on “pay for performance” - align executive compensation with
the overall short and long-term company objectives and with individual
functional objectives;
|
·
|
Attract,
motivate and retain key talent – remain competitive while
attracting and retaining the executive talent required to successfully
implement our business strategy;
and
|
·
|
Align
the financial interests of our executives with those of our stockholders –
place a significant amount of total direct compensation “at risk”
dependent upon performance of the Company. Thus a large portion
of the executive compensation is tied directly to the long-term
and short-term performance goals of the Company and the value
it creates for our stockholders.
|
·
|
Financial
Objectives
|
o
|
Raise
capital of targeted amount
|
o
|
Manage
loss to prescribed level
|
o
|
Manage
stock performance
|
o
|
Achieved
prescribed cash balance and improved
liquidity
|
o
|
Close
a commercialization partnership
|
o
|
Achieve
at least joint ownership of ‘231
patent
|
·
|
Commercial
and Operational Objectives
|
o
|
Initiate
EU introduction for Celution and achieve target
revenue
|
o
|
Initiate
StemSource sales in Japan and install target number of cell
banks
|
·
|
Clinical
and Regulatory Objectives
|
o
|
Achieve
enrollment goals for clinical
trials
|
o
|
Achieve
expanded product claims in EU and regulatory filings in
U.S.
|
o
|
Prepare
and submit regulatory filings in various Asian
countries
|
·
|
Research
and Development Objectives
|
o
|
Achieve
improved manufacturing efficiency that results in lower cost of goods
sold
|
o
|
Achieve
key research objectives to support clinical priorities, partnerships and
device development
|
o
|
Develop
next generation prototype
|
(a)
|
(b)
|
(c)
|
(d)
|
(e)
|
(f)
|
(g)
|
(h)
|
(i)
|
(j)
|
|||||||||
Name
and Principal Position
|
Year
|
Salary
|
Bonus(1)
|
Stock
Awards
|
Option
Awards(2)
|
Non-Equity
Incentive
Plan
Comp.
(3)
|
Change
in Pension Value and NQ Deferred Comp.
|
All
Other Comp-ensation
|
Total
|
|||||||||
Christopher
J. Calhoun,
Chief
Executive Officer (PEO)
|
2008
2007
2006
|
$ 420,012$ 420,012
$ 395,002
|
—
—
—
|
—
—
—
|
$ 256,339
$ 228,601
$ 250,952
|
—
$ 172,200
$
121,800
|
—
—
—
|
$
14,821
$ 10,501
$ 18,588
|
(4)
(4)
(4)
|
$ 691,172
$
831,314
$
786,342
|
||||||||
Marc
H. Hedrick, President
|
2008
2007
2006
|
$ 384,478
$ 372,312
$ 331,669
|
—
—
—
|
—
—
—
|
$ 180,645
$ 160,098
$ 170,767
|
—
$
124,100
$
84,863
|
—
—
—
|
$
116,985
—
$ 13,764
|
(7)
(5)
(6)
|
$
682,108
$
656,510
$
601,063
|
||||||||
Mark
E. Saad,
Chief
Financial Officer (PFO)
|
2008
2007
2006
|
$ 350,015
$ 350,015
$ 329,169
|
—
—
—
|
—
—
—
|
$ 181,678
$ 193,890
$ 232,433
|
—
$
99,225
$
63,438
|
—
—
—
|
—
—
$
10,838
|
(5)
(5)
(7)
|
$
531,693
$
643,130
$
635,878
|
||||||||
Seijiro
N. Shirahama,
President
– Asia Pacific
|
2008
2007
2006
|
$ 260,000
$ 239,167
$ 214,810
|
—
—
—
|
—
—
—
|
$ 161,854
$ 151,606
$ 227,636
|
—
$
55,250
$
36,425
|
—
—
—
|
—
—
—
|
(5)
(5)
(5)
|
$
421,854
$
446,023
$ 478,871
|
||||||||
Bruce
A. Reuter,
Sr.
Vice President – Int’l Sales, Marketing & Distribution
|
2008
2007
2006
|
$ 254,830
$ 219,469
$ 210,001
|
—
—
—
|
—
—
—
|
$ 104,910
$ 81,780
$ 192,198
|
—
$
46,575
—
|
—
—
—
|
$ 91,991
—
$
10,274
|
(8)
(5)
(8)
|
$ 451,731
$
347,824
$
412,473
|
(1)
|
Column
(d) is used to record non-equity discretionary (non-incentive based)
bonuses made to our NEOs. We did not provide such bonuses in
the fiscal years presented, therefore nothing is reflected in this column.
Cash bonuses paid under our EMIC Plan are disclosed in column
(g).
|
(2)
|
This
column represents the dollar amount recognized for financial statement
reporting purposes during the fiscal years presented for the fair value of
stock options granted to each of the named executives, in 2008 as well as
prior fiscal years, in accordance with FAS 123R. Pursuant to
the SEC rules, the amounts shown exclude the impact of estimated
forfeitures related to service-based vesting conditions. For additional
information on the valuation assumptions with respect to the 2008 grants,
refer to note 16 of the financial statements in our Annual Report on Form
10-K, as filed with the SEC on March 13,
2009.
|
(3)
|
The
amounts in column (g) reflect the cash awards under the 2008 EMIC Plan,
which is discussed in further detail in the CD&A under the heading
“2008 NEO Compensation – Executive Management Incentive
Compensation Plan.”
|
(4)
|
All
Other Compensation for Mr. Calhoun for 2008 includes supplemental
long-term disability insurance premiums ($9,591) and supplemental term
life insurance premiums ($3,230), and a tax preparation fee allowance
($2,000). All Other Compensation for Mr. Calhoun for 2007
includes supplemental long-term disability insurance premiums ($4,058),
supplemental term life insurance premiums ($3,494), a tax preparation fee
allowance ($2,000), and airfare for Mr. Calhoun’s spouse to attend the
Company’s offsite management conference ($949). All Other
Compensation for Mr. Calhoun for 2006 includes supplemental long-term
disability insurance premiums ($3,433), supplemental term life insurance
premiums ($2,155), an automobile allowance ($11,000), and a tax
preparation fee allowance ($2,000).
|
(5)
|
Dollar
value of the Named Executive Officer’s perquisites and other personal
benefits was less than $10,000 for the year
reported.
|
(6)
|
All
Other Compensation for Dr. Hedrick for 2008 includes supplemental
long-term disability insurance premiums ($9,035), a tax preparation fee
allowance ($2,000), and foreign relocation reimbursement for temporary
housing ($51,000), automobile cost reimbursement and personal and family
travel expenses ($54,950). All Other Compensation for Dr.
Hedrick for 2006 includes supplemental long-term disability insurance
premiums ($1,764), an automobile allowance ($10,000), and a tax
preparation fee allowance ($2,000).
|
(7)
|
All
Other Compensation for Mr. Saad for 2006 includes supplemental long-term
disability insurance premiums ($838), an automobile allowance ($8,000),
and a tax preparation fee allowance
($2,000).
|
(8)
|
All
Other Compensation for Mr. Reuter for 2008 includes supplemental long-term
disability insurance premiums ($3,208), a tax preparation fee allowance
($2,000), and foreign relocation reimbursement for temporary housing and
home maintenance ($76,443) and automobile cost reimbursement and personal
and family travel expenses ($10,340). All Other Compensation
for Mr. Reuter for 2006 includes supplemental long-term disability
insurance premiums ($2,674), an automobile allowance ($5,600), and a tax
preparation fee allowance ($2,000).
|
(a)
|
(b)
|
(c-e)
|
(f-h)
|
(i)
|
(j)
|
(k)
|
(l)
|
(m)
|
||||||||||||||||
Potential
2008 Payouts Under Non-Equity Incentive Plan Awards
|
Estimated
Future Payouts Under Equity Incentive Plan Awards
|
All
Other Stock Awards:
|
All
Other Option Awards:
|
Exercise
or
|
Full
Grant Date Fair
|
|||||||||||||||||||
Named
Officers
|
Grant
Date
|
Thre-shold
($)
|
Target
($)
|
Ma
xi-mum
($)
|
Thresh-old
(#)
|
Tar-get
(#)
|
Ma
xi-
mu
m
(#)
|
Number
of Shares of Stock or Units
(#)
|
Number
of Securities Underlying Options
(#)
|
Base
Price of Option Awards ($/Sh)
|
Market
Price on Date of Grant
($/Sh)
|
Value
of Stock and Option Awards ($)(1)
|
||||||||||||
Christopher
J. Calhoun,
Chief
Executive Officer
|
1/31/2008
|
–
|
$
210,000
|
–
|
–
|
–
|
–
|
–
|
85,000
|
$5.14
|
$5.14
|
$
231,692
|
||||||||||||
Marc
H. Hedrick,
President
|
1/31/2008
|
–
|
$
146,000
|
–
|
–
|
–
|
–
|
–
|
60,000
|
$5.14
|
$5.14
|
$
163,548
|
||||||||||||
Mark
E. Saad,
Chief
Financial Officer
|
1/31/2008
|
–
|
$
122,500
|
–
|
–
|
–
|
–
|
–
|
55,000
|
$5.14
|
$5.14
|
$
149,919
|
||||||||||||
Seijiro
N. Shirahama,
President
– Asia Pacific
|
1/31/2008
|
–
|
$
65,000
|
–
|
–
|
–
|
–
|
–
|
55,000
|
$5.14
|
$5.14
|
$
149,919
|
||||||||||||
Bruce
A. Reuter,
Sr.
Vice President – Int’l Sales, Marketing & Distribution
|
1/31/2008
|
–
|
$
57,500
|
–
|
–
|
–
|
–
|
–
|
30,000
|
$5.14
|
$5.14
|
$
81,774
|
(1)
|
Computed
in accordance with FAS 123R. See note 16 of the financial statements in
our Annual Report on Form 10-K, as filed with the SEC on March 13, 2009
regarding assumptions underlying valuation of equity
awards.
|
(a)
|
(b)
|
(c)
|
(d)
|
(e)
|
(f)
|
(g)
|
(h)
|
(i)
|
(j)
|
(k)
|
||||||||||
Option
Awards
|
Stock
Awards
|
|||||||||||||||||||
Name
|
Option
Grant Date
(1)
|
Number
of
Securities
Underlying Unexercised Options
(#)
Exercisable
|
Number
of Securities Underlying Unexercised Options
(#)
Un-Exercisable
(2)
|
Equity
Incentive
Plan Awards: Number of Securities Underlying Unexercised Unearned
Options
(#)
|
Option
Exercise Price
($)
|
Option
Expiration
Date
|
Number
of Shares or Units of Stock That Have Not Vested
(#)
|
Market
Value of Shares or Units of Stock That Have Not Vested
($)
|
Equity
Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights
That Have Not Vested
(#)
|
Equity
Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or
Other Rights That Have Not Vested
($)
|
||||||||||
Christopher
J. Calhoun,
Chief
Executive Officer
|
1/1/2000
1/3/2001
2/8/2002
1/28/2003
6/2/2004
2/2/2005
1/24/2006
2/26/2007
1/31/2008
|
62,500
200,000
205,000
200,000
75,000
95,832
72,916
32,083
19,479
|
—
—
—
—
—
4,168
27,084
37,917
65,521
|
—
—
—
—
—
—
—
—
—
|
$3.00
$7.06
$3.09
$4.40
$4.16
$3.12
$7.04
$5.44
$5.14
|
1/1/2010
1/3/2011
2/8/2012
1/28/2013
6/2/2014
2/2/2015
1/24/2016
2/26/2017
1/31/2018
|
—
—
—
—
—
—
—
—
—
|
—
—
—
—
—
—
—
—
—
|
—
—
—
—
—
—
—
—
—
|
—
—
—
—
—
—
—
—
—
|
||||||||||
Marc
H. Hedrick,
President
|
11/14/2002
1/28/2003
6/2/2004
2/2/2005
1/24/2006
2/26/2007
1/31/2008
|
150,000
25,000
50,000
67,082
51,041
22,916
13,750
|
—
—
—
2,918
18,959
27,084
46,250
|
—
—
—
—
—
—
—
|
$4.15
$4.40
$4.16
$3.12
$7.04
$5.44
$5.14
|
11/14/2012
1/28/2013
6/2/2014
2/2/2015
1/24/2016
2/26/2017
1/31/2018
|
—
—
—
—
—
—
—
|
—
—
—
—
—
—
—
|
—
—
—
—
—
—
—
|
—
—
—
—
—
—
—
|
||||||||||
Mark
E. Saad,
Chief
Financial Officer
|
6/21/2004
2/2/2005
1/24/2006
2/26/2007
1/31/2008
|
190,000
67,082
51,041
22,916
12,604
|
—
2,918
18,959
27,084
42,396
|
—
—
—
—
—
|
$4.12
$3.12
$7.04
$5.44
$5.14
|
6/21/2014
2/2/2015
1/24/2016
2/26/2017
1/31/2018
|
—
—
—
—
—
|
—
—
—
—
—
|
—
—
—
—
—
|
—
—
—
—
—
|
||||||||||
Seijiro
N. Shirahama,
President
– Asia Pacific
|
10/28/2002
6/2/2004
2/2/2005
12/8/2005
1/24/2006
2/26/2007
11/15/2007
1/31/2008
|
75,000
25,000
33,541
37,499
25,520
13,750
6,771
12,604
|
—
—
1,459
12,501
9,480
16,250
18,229
42,396
|
—
—
—
—
—
—
—
—
|
$4.14
$4.16
$3.12
$6.86
$7.04
$5.44
$5.35
$5.14
|
10/28/2012
6/2/2014
2/2/2015
12/8/2015
1/24/2016
2/26/2017
11/15/2017
1/31/2018
|
—
—
—
—
—
—
—
—
|
—
—
—
—
—
—
—
—
|
—
—
—
—
—
—
—
—
|
—
—
—
—
—
—
—
—
|
||||||||||
Bruce
A. Reuter,
Sr.
Vice President – Int’l Sales, Marketing & Distribution
|
1/2/2001
9/17/2001
2/8/2002
1/28/2003
6/2/2004
2/2/2005
1/24/2006
11/9/2006
2/26/2007
1/31/2008
|
100,000
35,000
30,000
29,895
13,020
12,396
4,375
36,458
13,750
6,875
|
—
—
—
—
—
—
—
33,542
16,250
23,125
|
—
—
—
—
—
—
—
—
—
—
|
$7.34
$2.51
$3.09
$4.40
$4.16
$3.12
$7.04
$4.68
$5.44
$5.14
|
1/2/2011
9/17/2011
2/8/2012
1/28/2013
6/2/2014
2/2/2015
1/24/2016
11/9/2016
2/26/2017
1/31/2018
|
—
—
—
—
—
—
—
—
—
—
|
—
—
—
—
—
—
—
—
—
—
|
—
—
—
—
—
—
—
—
—
—
|
—
—
—
—
—
—
—
—
—
—
|
(1)
|
For
a better understanding of this table, we have included an additional
column showing the grant date of the stock
options.
|
(2)
|
Generally,
awards issued under the 1997 or 2004 plans are subject to four-year
vesting, and have a contractual term of 10 years. Awards
presented in this table contain one of the following two vesting
provisions:
|
·
|
25%
of a granted award vests after one year of service, while an additional
1/48 of the award vests at the end of each month thereafter for 36 months,
or
|
·
|
1/48
of the award vests at the end of each month over a four-year
period.
|
(a)
|
(b)
|
(c)
|
(d)
|
(e)
|
||||
Option
Awards
|
Stock
Awards
|
|||||||
Name
|
Number
of Shares Acquired on Exercise
(#)
|
Value
Realized on Exercise
($)
|
Number
of Shares Acquired on Vesting
(#)
|
Value
Realized on Vesting
($)
|
||||
Christopher
J. Calhoun,
Chief
Executive Officer
|
53,190
|
$471,010
|
—
|
—
|
||||
Marc
H. Hedrick,
President
|
—
|
—
|
—
|
—
|
||||
Mark
E. Saad,
Chief
Financial Officer
|
—
|
—
|
—
|
—
|
||||
Seijiro
N. Shirahama,
President
– Asia Pacific
|
—
|
—
|
—
|
—
|
||||
Bruce
A. Reuter,
Sr.
Vice President – Int’l Sales, Marketing & Distribution
|
—
|
—
|
—
|
—
|
Acquisition(2)
|
Forced
Separation Due to Acquisition(3)
|
|||||||
PAYMENTS
DUE UPON ACQUISITION / TERMINATION(1):
|
||||||||
Cash
Severance
|
||||||||
Base
Salary(4)
|
$ | — | $ | 630,000 | ||||
Benefits
|
||||||||
COBRA
Premiums
|
— | $ | 29,374 | |||||
Long-Term
Incentives
|
||||||||
Value
of Accelerated Stock Options(5)
|
2,042 | 2,042 | ||||||
TOTAL
VALUE
|
$ | 2,042 | $ | 661,416 | ||||
Acquisition(2)
|
Forced
Separation Due to Acquisition(3)
|
|||||||
PAYMENTS
DUE UPON ACQUISITION / TERMINATION(1):
|
||||||||
Cash
Severance
|
||||||||
Base
Salary(4)
|
$ | — | $ | 365,000 | ||||
Benefits
|
||||||||
COBRA
Premiums
|
— | 19,582 | ||||||
Long-Term
Incentives
|
||||||||
Value
of Accelerated Stock Options(5)
|
1,430 | 1,430 | ||||||
TOTAL
VALUE
|
$ | 1,430 | $ | 386,012 | ||||
Acquisition(2)
|
Forced
Separation Due to Acquisition(3)
|
|||||||
PAYMENTS
DUE UPON ACQUISITION / TERMINATION(1):
|
||||||||
Cash
Severance
|
||||||||
Base
Salary(4)
|
$ | — | $ | 350,000 | ||||
Benefits
|
||||||||
COBRA
Premiums
|
— | 19,582 | ||||||
Long-Term
Incentives
|
||||||||
Value
of Accelerated Stock Options(5)
|
1,430 | 1,430 | ||||||
TOTAL
VALUE
|
$ | 1,430 | $ | 371,012 | ||||
(1)
|
Assumes
a triggering event occurred on December 31,
2008.
|
(2)
|
Based
on the occurrence of an acquisition of the Company, provided that the
executive is at that time still in the service of the
Company.
|
(3)
|
Based
on the occurrence of both actual or constructive termination without good
cause in the context of an acquisition of the Company as described in
detail in the section above titled, Company
Acquisition/Post-Termination
Compensation.
|
(4)
|
Based
on the executive’s annual base salary on December 31, 2008, which was
$420,000 for Mr. Calhoun; $365,000 for Dr. Hedrick; and $350,000 for Mr.
Saad.
|
(5)
|
Based
on the difference between the aggregate exercise price of all accelerated
in-the-money stock options and the aggregate market value of the
underlying shares, calculated based on the per-share closing market price
of our common stock on December 31, 2008,
$3.61.
|
(a)
|
(b)
|
(c)
|
(d)
|
(e)
|
(f)
|
(g)
|
(h)
|
|||||||
Director
Name(1)
|
Fees
Earned or Paid in Cash(2)
($)
|
Stock
Awards
($)
|
Option
Awards(3)(4)
($)
|
Non-Equity
Incentive Plan Compensation ($)
|
Change
in Pension Value and Nonqualified Deferred Compensation
Earnings
($)
|
All
Other Compensation ($)
|
Total
($)
|
|||||||
Ronald
D. Henriksen, Chairman
|
$
65,500
|
–
|
$
126,637
|
–
|
–
|
–
|
$
192,137
|
|||||||
Richard
J. Hawkins
|
$
34,500
|
–
|
$
76,036
|
–
|
–
|
–
|
$
110,536
|
|||||||
Paul
W. Hawran
|
$
52,000
|
–
|
$
121,420
|
–
|
–
|
–
|
$
173,420
|
|||||||
E.
Carmack Holmes, MD
|
$
30,500
|
–
|
$
120,392
|
–
|
–
|
–
|
$
150,892
|
|||||||
David
M. Rickey
|
$
48,000
|
–
|
$
120,392
|
–
|
–
|
–
|
$
168,392
|
(1)
|
Mr.
Calhoun and Dr. Hedrick are not included in this table as they are
employees of the Company and receive no extra compensation for their
services as a Director. The compensation received by Mr. Calhoun and Dr.
Hedrick as employees of the Company is shown in the Summary Compensation
Table and the three stock-option-related tables
above.
|
(2)
|
In
fiscal 2008, each non-employee director received a $5,000 quarterly
retainer, a fee of $2,000 per quarterly meeting attended, and a fee of
$2,000 per special meeting attended in person. Attendance of
telephonic meetings was compensated at $500 per
meeting. Compensation Committee members received $2,000 per
meeting attended, Governance and Nominating Committee members received
$2,000 per meeting attended, Audit Committee members received $2,000 per
meeting attended, and Special Pricing Committee members received $500 per
meeting attended. The Chairman of the Board received an additional annual
stipend of $15,000, the Chairman of the Audit Committee received an
additional annual stipend of $10,000, and the Chairmen of the Compensation
Committee and the Governance and Nominating Committee each received an
additional annual stipend of
$7,500.
|
(3)
|
Column
(d) represents the dollar amount recognized for financial statement
reporting purposes with respect to the 2008 fiscal year for the fair value
of stock options previously granted to the directors, in 2008 as well as
prior fiscal years, in accordance with FAS 123R. Pursuant to the SEC
rules, the amounts shown exclude the impact of estimated forfeitures
related to service-based vesting conditions. For additional information on
the valuation assumptions with respect to the 2008 grants, refer to note
16 of the financial statements in our Annual Report on Form 10-K, as filed
with the SEC on March 13, 2009.
|
(4)
|
As
of December 31, 2008, the following directors held options to purchase the
respective number of shares of our common stock: Richard J. Hawkins
50,000; Paul W. Hawran 125,000; Ronald D. Henriksen 250,000; E. Carmack
Holmes 195,000; David M. Rickey
110,000.
|
Equity
Compensation Paid to Directors for Fiscal Year 2008
|
||||||||||||
(a)
|
(b)
|
(c)
|
(d)
|
(e)
|
(f)
|
(g)
|
||||||
Director
Name
|
Grant
Date
|
Option
Awards
(#)
|
Grant
Date Fair Value of Option Awards
($)
|
Stock
Awards
(#)
|
Grant
Date Fair Value of Stock Awards
($)
|
Total
Value of Equity Awards for 2008
($)
|
||||||
Ronald
D. Henriksen
|
1/31/2008
|
25,000
|
$ 68,145
|
(1)
|
–
|
–
|
$ 68,145
|
|||||
Richard
J. Hawkins
|
–
|
–
|
–
|
(2)
|
–
|
–
|
–
|
|||||
Paul
W. Hawran
|
1/31/2008
|
20,000
|
$ 54,516
|
(1)
|
–
|
–
|
$ 54,516
|
|||||
E.
Carmack Holmes, MD
|
1/31/2008
|
20,000
|
$ 54,516
|
(1)
|
–
|
–
|
$ 54,516
|
|||||
David
M. Rickey
|
1/31/2008
|
20,000
|
$ 54,516
|
(1)
|
–
|
–
|
$ 54,516
|
(1)
|
The
grant date fair value of the option award granted was $2.73 per
share.
|
(2)
|
Mr.
Hawkins was not granted stock options in 2008, as he received a grant upon
his appointment to the Board in December
2007.
|
Plan
Category
|
Number
of securities to be issued upon exercise of outstanding options, warrants
and rights
|
Weighted-average
exercise
price
of outstanding options, warrants and rights
|
Number
of securities remaining available for future issuance under equity
compensation plans (excluding securities reflected in column
(a))
|
||||
(a)
|
(b)
|
(c)
|
|||||
Equity
compensation plans approved by security holders(1)
|
3,810,395
|
$4.65
|
—
|
||||
Equity
compensation plans not approved by security holders(2)
|
2,118,312
|
$5.68
|
2,190,450
|
||||
Total
|
5,928,707
|
$5.02
|
2,190,450
|
(1)
|
The
1997 Stock Option and Stock Purchase Plan expired on October 22,
2007.
|
(2)
|
The
maximum number of shares shall be cumulatively increased on the first
January 1 after the Effective Date, August 24, 2004, and each January 1
thereafter for 9 more years, by a number of shares equal to the lesser of
(a) 2% of the number of shares issued and outstanding on the immediately
preceding December 31, and (b) a number of shares set by the
Board.
|
2008
|
2007
|
||
Audit
fees (1)
|
$ 684,152
|
$ 630,746
|
|
Audit
related fees (2)
|
—
|
—
|
|
Tax
Fees (3)
|
—
|
$
4,775
|
|
All
other fees (4)
|
—
|
—
|
|
Total
|
$ 684,152
|
$ 635,521
|
(1)
(1)
|
Audit
fees consist of fees for professional services performed by KPMG LLP for
the integrated audit of our annual financial statements (and internal
control over financial reporting) included in our Form 10-K filing and
review of financial statements included in our quarterly Form 10-Q
filings, reviews of registration statements and issuances of consents, and
services that are normally provided in connection with statutory and
regulatory filings or engagements.
|
|
(2)
(2)
|
Audit
related fees consist of fees for assurance and related services performed
by KPMG LLP that are reasonably related to the performance of the audit or
review of our financial statements. No such fees were incurred
in 2008 or 2007.
|
|
(3)
(3)
|
Tax
fees consist of fees for professional services performed by KPMG LLP with
respect to tax compliance, tax advice and tax planning. In
2007, these fees were related to support services provided in connection
with the transition of tax return preparation, tax advice and
consultation, to another firm. No such fees were incurred in
2008.
|
|
(4)
(4)
|
All
other fees consist of fees for other permissible work performed by KPMG
LLP that does not meet with the above category descriptions. No
such fees were incurred in 2008 or
2007.
|
C/O
COMPUTERSHARE
250 ROYALL STREET
font>
CANTON, MA 02021
|
VOTE BY INTERNET - www.proxyvote.com
Use the
Internet to transmit your voting
instructions and for electronic
delivery of information up until 11:59 P.M. Eastern
Time the day before the
cut-off
date or meeting date. Have your
proxy card in hand when
you
access the web
site and follow the instructions to obtain your records and
to create an electronic voting instruction form.
ELECTRONIC DELIVERY OF STOCKHOLDER COMMUNICATIONS
If you would like to reduce the costs incurred by Cytori Therapeutics, Inc.
in mailing proxy materials, you can consent to receiving all current
and
future proxy
statements, proxy cards and annual reports electronically via e-mail
or the
Internet. To sign up for electronic delivery, please follow the
instructions
above to vote using the Internet and, when prompted, indicate that you
agree to receive or access stockholder communications electronically in
future years.
VOTE BY PHONE - 1-800-690-6903
Use any touch-tone telephone to transmit your voting instructions up until
11:59 P.M. Eastern Time the day before the cut-off date or meeting date.
Have your proxy card in hand when you call and then follow the instructions.
VOTE BY MAIL
Mark,
sign and date your proxy card
and return it in the
postage-paid
envelope
we have provided or return it to
Cytori Therapeutics, Inc.,
c/o Broadridge, 51 Mercedes Way, Edgewood, NY 11717.
|
TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS: |
CYTTH1 KEEP THIS PORTION FOR YOUR RECORDS
|
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - | - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - |
THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED. | DETACH AND RETURN THIS PORTION ONLY |
CYTORI THERAPEUTICS, INC. | |
|
|
Vote On Directors | Vote On Proposal |
1. The Board of Directors recommends a vote
FOR each of the listed director nominees.
|
For
|
Against
|
Abstain
|
The Board of Directors recommends a vote
FOR the following proposal.
|
For
|
Against
|
Abstain
|
|
1a - Ronald
D. Henriksen
|
o
|
o
|
o
|
2. To
ratify the selection of KPMG LLP as independent
registered public
accounting firm of Cytori for
the fiscal year ending
December 31, 2009.
|
o
|
o
|
o
|
|
1b - Christopher
J. Calhoun
|
o
|
o
|
o
|
|
||||
1c -
Marc H. Hedrick, MD
1d - Richard J. Hawkins
|
o
o
|
o
o
|
o
o
|
3.
By my signature below, I confer to the named proxies
discretionary authority on any other business that may properly
come before
the Annual Meeting or any postponement
of the Annual Meeting.
|
o
|
o
|
o
|
|
1e - Paul
W. Hawran
|
o
|
o
|
o
|
|
||||
1f
- E. Carmack Holmes, MD
|
o
|
o
|
o
|
|||||
1g
- David M. Rickey
|
o
|
o
|
o
|
Please sign exactly as your name appears on this card. When signing as
an attorney, executor, administrator, trustee or guardian, please give your
full title. If shares are held jointly, each stockholder should sign.
|
||
Signature [PLEASE SIGN WITHIN BOX] Date | Signature (Joint Owners) Date |
Proxy - CYTORI THERAPEUTICS, INC.
|
PROXY SOLICITED BY THE BOARD OF DIRECTORS
FOR THE ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON AUGUST 13, 2009
The undersigned hereby appoints Christopher J. Calhoun and Marc H. Hedrick, MD, or either of them, as proxy holders each
with full power of substitution, to appear on behalf and to vote all shares of common stock of Cytori Therapeutics, Inc.
(the "Company") that the undersigned is entitled to vote at the Annual Meeting of Stockholders of the Company to be held on
August 13, 2009, and at any postponement thereof.
When properly executed, this proxy will be voted as directed. If properly executed and no instructions are specified, this proxy
will be voted FOR the election of the listed Nominees as Directors and FOR the ratification of the selection of KPMG LLP to
function as the Company's Independent Registered Public Accounting firm.
PLEASE COMPLETE, DATE AND
0;SIGN THIS PROXY AND RETURN IT IN THE ACCOMPANYING ENVELOPE.
|